Navigation Links
UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
Date:4/3/2012

al information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of April 4, 2012 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013 /PRNewswire-iReach/ -- MarketReportsOnline.com ... China Pharmaceutical Guidebook Series (4) 2013 Edition Material ... for Imported Drug Registration: A Guidebook of Registration ... Medicines " to its online database. ... Chinese medicines are always regarded by occidental as ...
(Date:5/22/2013)... and VANCOUVER, British Columbia , May 22, ... a leader in the development of novel therapeutics to target ... trials of its investigational compounds, custirsen and OGX-427, will be ... Annual Meeting of the American Society of Clinical Oncology ... 31 – June 4. Despite the availability ...
(Date:5/21/2013)... BEIJING, May 21, 2013 Concord Medical Services ... CCM ), a leading specialty hospital management solution ... and diagnostic imaging centers in China and the parent ... results for the first quarter ended March 31, 2013 ... , Total net revenue, which consists of net revenues ...
Breaking Medicine Technology:China Pharmaceutical Market Guidebook Series (4) 2013 Report 2China Pharmaceutical Market Guidebook Series (4) 2013 Report 3China Pharmaceutical Market Guidebook Series (4) 2013 Report 4China Pharmaceutical Market Guidebook Series (4) 2013 Report 5OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 2OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 3OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 4OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 5Concord Medical Reports First Quarter 2013 Financial Results 2Concord Medical Reports First Quarter 2013 Financial Results 3Concord Medical Reports First Quarter 2013 Financial Results 4Concord Medical Reports First Quarter 2013 Financial Results 5Concord Medical Reports First Quarter 2013 Financial Results 6Concord Medical Reports First Quarter 2013 Financial Results 7Concord Medical Reports First Quarter 2013 Financial Results 8Concord Medical Reports First Quarter 2013 Financial Results 9Concord Medical Reports First Quarter 2013 Financial Results 10Concord Medical Reports First Quarter 2013 Financial Results 11Concord Medical Reports First Quarter 2013 Financial Results 12Concord Medical Reports First Quarter 2013 Financial Results 13
... of Inflammatory ... ... MOUNTAIN VIEW, Calif., May 13 ChemoCentryx, Inc., today,announced the initiation ... molecule compound designed to specifically,target the CCR1 chemokine receptor which is ...
... Business, DUBLIN, Ohio, May 12 Cardinal ... improve the safety and,productivity of health care, today ... privately held Enturia, Inc., the manufacturer of,infection prevention ... ChloraPrep(R) brand products are used widely in U.S. ...
Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 2ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 3ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 4ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 5Cardinal Health Completes Enturia Acquisition 2
(Date:5/21/2013)... 2013 The University of Colorado’s Anschutz ... HEALTHY DINING to help Coloradans make healthier choices when ... program is called HEALTHY DINING IN COLORADO. More ... participating in Colorado. Restaurants will offer a selection of ... lean protein, vegetables, fruits, whole grains and unsaturated fats. ...
(Date:5/21/2013)... May 22, 2013 Swimsuit season is almost ... Whisperer ® products has begun with a 35% discount. , ... estrogen. Many women get the dreaded cellulite even if they ... the skin where they have been stored as toxic lymph ... no easy fixes, a specific program that works to dissolve ...
(Date:5/21/2013)... Dallas, Texas (PRWEB) May 22, 2013 ... globally increasing meat production industry value chain. Most of ... the form of injectable, pellets, liquids, and powders. There ... in different quantities and concentrations depending upon the type ... acids, minerals, and vitamins that provide essential nutrition to ...
(Date:5/21/2013)... George Washington (GW) University School of Public ... launch of the Avance Center for the ... SPHHS, the Maryland Multicultural Youth Centers, the ... university-community partnership aims to address public health ... research, mutual capacity building and prevention efforts. ...
(Date:5/21/2013)... Medical Ministry International announced today that it has ... GreatNonprofits , the leading provider of user reviews about nonprofit ... 2013 Nonprofit,” says Samuel Smith, MMI CEO. This does ... and Staff serving in 22 countries around the world. This ... have seen our work first hand and wanted to tell ...
Breaking Medicine News(10 mins):Health News:Colorado Takes a Huge Step toward Transforming the Family Dining Experience 2Health News:Colorado Takes a Huge Step toward Transforming the Family Dining Experience 3Health News:Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale" 2Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 2Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 3Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 4Health News:GW launches center to address health disparities in the Latino immigrant community 2Health News:GW launches center to address health disparities in the Latino immigrant community 3Health News:Medical Ministry International Recognized as a 2013 Top-rated Nonprofit By GreatNonprofits.org 2
... U.S. organ transplant system often fails to detect or fix ... according to the Los Angeles Times on Sunday. ... are usually kept a secret leaving patients and their families ... ,This nonprofit agency has been given the contract ...
... at the Indian Institute of Technology (IIT), Chennai, have ... them into cells, a// major step towards drug efficacy. ... that comprises a core of one material and a ... of delivering therapeutic molecules into cells and monitoring it ...
... 80% accuracy in prediction of the most effective drug against ... test that examines the// genetic material of a patient’s tumour. ... North Carolina report that this genomic test is useful in ... a particular cancer but also a combination of drugs. ...
... chefs are two to four times bigger than the government's ... contributing to increasing weight of their diners, the chefs believe ... ,These were the findings that were revealed by a ... the Obesity Society. ,A meal at a restaurant ...
... and bad news for women faced with the decision about ... is that screening mammography does reduce breast cancer mortality. The ... less likely to die of breast cancer than women who ... that women in a screened population are 30 percent more ...
... provide a scientific basis for eventual treatment, neurology researchers ... of a protein that// helps keep brain activity in ... to be an underlying reason for seizures and memory ... brain injury (TBI). ,“A traumatic brain injury ...
Cached Medicine News:Health News:Flaws Reported in overview of US organ transplants 2Health News:Now, Silica Nanobubbles for Targeted Drug Delivery 2Health News:Genomic tests for better cancer treatment 2Health News:Portion Sizes in Restaurants Larger than Before 2Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 2Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 3Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 4Health News:How Brain Injury Leads to Seizures, Memory Problems 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: